Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mar

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Female Reproductive Cancers Linked to Reduced Survival Advantage Over Males

p53 Reactivator Rezatapopt in TP53 Y220C–Mutated Solid Tumors

BCMA CAR T-Cell Therapy in Newly Diagnosed Multiple Myeloma

Disease Stage at Breast Cancer Diagnosis Impacted by Region Race and Insurance

Can Viral Respiratory Infections Increase Lung Cancer Risk